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AbstrAct
Objectives: To monitor the release of the antifungal drugs Fluconazole, Chlorhexidine and a com-
bination of the two from an auto-polymerized poly (methyl methacrylate) (PMMA) denture base resin; 
and to investigate the effect of the released drugs upon the growth of Candida albicans. 
Methods: A high performance liquid chromatography-Ultra violet (HPLC-UV)  method was used 
in the analysis of the released drugs into distilled water from PMMA discs doped with the antifungal 
drugs Fluconazole (10%), Chlorhexidine (10%) and a combination of the two drugs (5% each). The an-
tifungal efficacy of the released drugs was monitored, microbiologically, employing “well” technique 
on a Saborauds culture medium inoculated with a resistant strain of Candida albicans.  
 Results: It was shown that Fluconazole, Chlorhexidine and the combination of the two drugs can 
be successfully incorporated with PMMA. It was found that the drugs leach steadily out of the PMMA 
resin into distilled water at mouth temperature and that sustained drug release continued throughout 
the 28 days test period. It was also shown that the released drugs demonstrated an antifungal activity 
against the resistant Candida albicans and this was most remarkable in the combined drugs samples.
Conclusions: The findings of this investigation have a clinical value in terms of their significant 
contribution to the treatment of fungal infections of the oral cavity. The sustained release of anti-
fungal drugs from the PMMA resin clearly constitutes a new dosage form of these drugs via the poly 
(methyl methacrylate) delivery system. (Eur J Dent 2009;3:257-266)
Key words: Fluconazole; Chlorhexidine; Synergism; Auto-polymerized PMMA; Eluates; Antifungal 
drug; HPLC-UV; Denture stomatitis; Candida albicans.
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The Candida-associated denture stomatitis is 
a common condition characterized by generalized 
inflammation of the palatal mucosa covered by the 
denture.1,2 It is a harmless form of oral candidiasis 
and is associated with a quantitative increase of 
yeasts on the mucosa and the denture’s fit sur-
face.2 Usually a mixture of Candida species such 
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as Candida albicans, Candida tropicals, Candida 
krusei, Candida guilliermondii, Candida parapsi-
losis, Candida glabrata can be isolated from oral 
candidal lesions. Candida albicans, however, has 
been claimed to be the principal pathogen that has 
a main role in the development of oral candidosis.3 
The presence of numerous yeasts may give rise to 
spreading to the angles of the mouth, the tongue, 
the pharynx, and the alimentary and respiratory 
tracts.4 The lesion may heal partially after topical 
antifungal treatment4,5 but the incidence of relapse 
is, however, very high.6-8 
Although  denture  induced  candidosis  could 
be treated by methods targeted towards the oral 
mucosa, other treatment modalities are directed 
toward the denture base. A number of effective 
antifungal agents have been administered, either 
topically or systemically, for management of oral 
candidosis.9 Amphotricin B and nystatin are com-
mon  topical  antifungal  agents,  whereas  azoles 
such as fluconazole and ketoconazole are avail-
able  as  systemic  antifungal  treatment.10  Signifi-
cant resistance in yeasts has been reported in iso-
lates from patients with prolonged neutropenia,11 
and in HIV patients.12
Chlorhexidine  gluconate,  an  antimicrobial 
agent, has been reported as an active against a 
broad  spectrum  of  organisms  including  Candi-
da.13,14 Although systemic dosage forms may be ef-
fective against mucosal lesions; they offer no cure 
to the Candida infested tissue surface of dentures. 
Persistent fungal presence on the denture’s fitting 
surface often leads to cross infection and recur-
rence  of  the  mucosal  lesions.  Candida  albicans 
has been found on both hard denture base acrylic 
resins and silicon-based resilient liner materials 
in vivo and in vitro.15 
Several researches investigated the feasibility 
of using drug delivery system by incorporation of 
antifungal or antimicrobial agents, with denture 
acrylic resin16 or with soft liners.17 The idea sug-
gested the use of polymerized acrylic as carriers 
for drugs orally.18 Similarly, soft liners placed in 
dentures have been used as carriers for antifungal 
drugs in treating denture stomatitis.19,20
It has been found that the release of the drug 
out of the polymeric carriers continued for more 
than 100 days.21 However, the physical properties 
of the resin were affected due to the presence of 
the drug particles, which may dissolve and result 
in porosity in the acrylic base.22
These formulations have been claimed of hav-
ing less side effects compared with the conven-
tional forms, because of the continual presence 
of the drug at the site of action, less amount of 
drug is needed to achieve the therapeutic effect.23 
They were also believed to be of high benefit for 
physically  or  mentally  compromised  patients.24 
An example of these formulations, in which sus-
tained topical administration of chlorhexidine via 
a self-cured polymeric system based on polyethyl 
methacrylate and tetrahydrofurfuryl methacrylate 
(PEM/THFM) had been advocated.25 
The methods of detecting the released antifun-
gal drug varied among investigators; some used 
spectrophotometric and agar diffusion measure-
ments  of  the  released  drug  into  water;21 others 
employed a proton nuclear magnetic resonance 
spectroscopy  for  the  same  purpose25  whereas 
some researchers used ultraviolet spectrometry 
in the measurement of drug release.26
All previous studies, except one, stopped short 
of investigating whether the concentration of the 
released antifungal drug into the surrounding me-
dium was adequate to produce the required role. 
One study,26 however used a turbidimetric mea-
surement of candidal growth after exposure to an 
experimental drug release device both with and 
without the antifungal drug. It was found that the 
drug-containing  test  samples  inhibited  candidal 
growth and survival, in vitro. The number of sur-
viving colony-forming unit/ml of culture medium 
was  substantially  reduced  for  the  test  sample 
compared to controls.
Nowadays HPLC is used for a wide range of 
applications and offers significant advantages in 
the analysis of pharmaceutical formulations and 
biological fluids. An added advantage is that many 
detectors used in HPLC are non-destructive, thus 
facilitating sample recovery.27
The present study aimed to formulating a med-
icated relining polymeric delivery system based on 
the conventional auto-polymerizing poly (methyl 
methacrylate) resin doped with 10% (w/w) antifun-
gal drug for sustained topical delivery of the drug 
for the treatment of denture-induced oral candi-
dosis.
The choice of the polymeric system was based 
on its abundance, ease of handling and cost ef-
fectiveness. The room-temperature polymerizing 
resin version was employed because it has been 
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proven  that  this  mode  of  polymerization  does 
not adversely affect the efficacy of the antifungal 
drugs.26 The employed polymer was intended for 
use as an indirect relining resin in order to avoid 
the possible thermal trauma to the denture bear-
ing mucosa that may be caused by the polymeriza-
tion exotherm.
The  antifungal  drugs  employed  in  the  study 
were fluconazole (10%); chlorhexidine (10%); and 
a  combination  of  fluconazole  and  chlorhexidine 
(5% each). The chosen concentration of the drugs, 
i.e., 10%, represents the maximum limit that has 
no  discernible  effect  on  the  preparation  of  the 
polymer samples,26 and at the same time it is the 
limit required to affect antifungal activity over the 
intended therapeutic period.
The inclusion of fluconazole in the study, de-
spite  previous  reports11,12  that  cast  doubt  on  its 
effectiveness against the azole resistant strains 
of Candida, was in order to: firstly, provide a mi-
crobiological evidence either for or against the re-
ported argument; and secondly, to acquire a base 
line data essential for comparing the antifungal 
efficacy of fluconazole-doped samples with those 
doped with chlorhexidine as well as with samples 
doped with the combined fluconazole/chlorhexi-
dine antifungal drugs. 
MAtErIALs And MEtHods
Sample preparation
A room temperature-polymerized poly (methyl 
methacrylate) acrylic resin, a product of (Paladur: 
powder  batch  No.  32,  liquid  batch  No.  012290) 
was  employed.  The  mixing  ratio  and  the  condi-
tions  for  processing  and  polymerization  recom-
mended  by  the  manufacturer  were  strictly  fol-
lowed. These were 5 g / 3 ml polymer powder/
monomer  liquid  ratio  for  mixing.  Three  groups 
of medicated samples were prepared (Figure 1). 
The first group was impregnated with 10% w/w 
Fluconazole powder; the second group with 10% 
Chlorhexidine  powder;  and  the  third  group  was 
impregnated  with  a  combination  of  Fluconazole 
5% w/w powder and Chlorhexidine 5% w/w pow-
der. The drugs were added in the specified ratio 
to the acrylic resin powder then the mixture of the 
powders with the liquid monomer were stirred for 
15 seconds and left standing for 4 minutes until 
plastic dough was formed. It was then packed in 
a specially constructed disc-shaped steel mould 
to produce a disc specimen (3.8 mm diameter and 
1.0 mm thickness). After packing the mould, it was 
allowed to stand for 13 minutes then placed in a 
pressure curing unit and cured at 55˚C and 2 bar 
pressure for 15 minutes.
High Performance Liquid Chromatography 
(HPLC)
Chemicals, reagents and standards
Acetonitril of HPLC–quality, hydrochloric acid 
and  sodium  citrate  of  analytical  grade  were  all 
purchased from GCC (England). The standard ma-
terial of the drugs, Fluconazole and Chlorhexidine, 
were  purchased  from  Cadilla  pharmaceuticals 
(Ahmad-Abad,  India).  The  internal  standard  p-
methyl phenol was purchased from ACROS (Geel, 
Belgium).
HPLC– Apparatus and working conditions
The analysis was carried out on an isocratic 
HPLC–apparatus (Figure 2) which consists of the 
following parts: HPLC pump type GBC (Australia), 
model LC 1110; HPLC injector type Rheodyne 7125 
(USA); HPLC-UV-Vis detector type GBC (Austra-
lia), model LC 1205; Integrator type Spectra Phys-
ics model LC 4290.
The HPLC apparatus was operated under the 
following working conditions: 
Eluent:  acetonitril  /  0.01M  phosphate  buf-
fer (25:75%); Eluent flow rate: 1.0 ml/min; Injec-
tion volume: 20 µl; Column: BDS – C18 (25 cm x 
4.6 mm, particle size 5 µm); Detector : UV – VIS 
–Spectrophotometer ( λ : 210 nm,  Range: 1.0); in-
tegrator chart speed: 0.5 cm / min, attenuation: 8
Figure 1. Discs of the three sample groups showing the drug 
release device (DRD) impregnated with 10% Fluconazole; 10% 
Chlorhexidine, and with a combination of 5% of each drug.
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Stock standard solutions and working stan-
dard solution
A 1000 µg/ml stock standard solution was pre-
pared for each drug by dissolving 10 mg of the 
drug in 10.0 ml HPLC-water. These prepared so-
lutions were kept in a refrigerator. 
The working standard solution for each drug, 
i.e., Fluconazole or Chlorhexidine, was prepared 
by mixing 20 µg/ml of the drug with 50 µg/ml of the 
internal standard p-methyl phenol in HPLC-water.
Leaching behavior
In the first group of samples, five discs, 6.27 
g each which contained 10% w/w of the Flucon-
azole  antifungal  drug  were  soaked  separately 
each in 60 ml distilled water. In the second group, 
five discs, 6.32 g each which contained 10% w/w of 
the Chlorhexidine antimicrobial drug were sepa-
rately soaked each in 60 ml distilled water. In the 
third group, five discs, 6.25 g each which contained 
5% w/w Fluconazole and 5% w/w Chlorhexidine 
were  soaked  separately  each  in  60  ml  distilled 
water.  The  15  containers  which  accommodat-
ed the samples (five disc specimens for each of 
the three groups) were left in a thermostatically 
controlled revolving water bath at 37°C. A small 
known amount of the test solution was taken from 
each container after soaking intervals of 2 hours, 
4 hours, 6 hours, 12 hours, 1 day, 2 days, 4 days, 1 
week, 2 weeks, 3 weeks and 4 weeks. The distilled 
water in the 15 containers was renewed at each 
test interval, in order to simulate the clinical situ-
ation regarding the dilution of the thin salivary film 
at the denture-mucosa interface.
At each time of analysis, the test solution of 
each  sample  group  was  taken  and  mixed  with 
aqueous solution of the internal standard of the 
corresponding sample, so that its concentration in 
the final volume (5 ml) becomes 50 µg/ml. 20 µl of 
this mixture solution was injected onto the HPLC-
column under the above mentioned conditions.
Qualitative and quantitative analysis
A representative chromatogram of a standard 
mixture of Fluconazole with internal standard is 
shown in Figure 3 and that for Chlorhexidine in 
Figure 4. A representative chromatogram of the 
standard  mixture  which  combined  Fluconazole 
and Chlorhexidine is shown in Figure 5.
The qualitative identification of each drug peak 
was performed through comparing the relative re-
tention time (RRT) of each drug, with respect to 
the internal standard p-methyl phenol in the real 
sample  to  those  (RRT)  in  the  chromatogram  of 
the standard mixture of the corresponding drug, 
which in this case 3.668 min for Fluconazole and 
8.020 min for Chlorhexidine (Figure 5). 
The quantitative determination was performed 
by using the relative peak areas (RPA) and the rel-
ative concentrations (RC). 
Microbiological investigation
Strains and media 
A strain of Candida albicans was isolated from 
an in-patient hospitalized at the Jordan University 
Hospital and was confirmed by biochemical tests. 
A reference strain of Candida albicans ATCC90028 
was used as a control. Until testing, the yeasts 
were kept frozen in Brain-Heart broth (Difco Lab-
oratories, Detroit, MI, USA) with 5% glycerol. For 
each experiment, the strains were sub-cultured 
twice on Saborauds agar (Difco) for 24h at 35°C 
Figure  2.  The  High  Performance  Liquid  Chromatography 
(HPLC) apparatus employed in the present investigation. 
Figure 3. A representative chromatogram of a standard mix-
ture of Fluconazole with the internal standard. 
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to ensure viability and purity. The inoculum sus-
pension was prepared by picking five colonies of 
at least 1 mm in diameter and suspending them in 
5 ml of sterile saline solution (0.85%).
The well diffusion test 
This  test  was  performed  using  Saborauds 
agar. The inoculum used was prepared using the 
yeasts from a 24-hour culture on Saborauds agar, 
a suspension was made in a sterile saline solution 
(0.85%). The turbidity of the suspension was adjust-
ed with a spectrophotometer at 530 nm to obtain a 
final concentration to match that of a 0.5 McFarland 
standard (0.5–2.5 × 103). The inoculated agar was 
poured into the assay plate (9 cm in diameter), and 
allowed to cool down on a leveled surface. Once the 
medium had solidified “wells” each 4 mm in diam-
eter, were cut out of the agar (Figure 7), and 20 µl of 
the eluates from Fluconazole (10%), Chlorhexidine 
(10%), and the combination drug (5% Fluconazole + 
5% Chlorhexidine) were placed each into a well in 
separate assay plates. Control cups containing the 
Drug Release Device (DRD) “Control” alone were 
also included in each assay plate (Figures 8-10).   
The plates were incubated at 35°C for 72 hours.
The  absence  of  growth  of  Candida  albicans, 
demonstrated by the occurrence of growth inhibi-
tion zone around the wells that contained the DRD 
supplemented with the drugs was interpreted as 
antifungal activity of the drugs. The antifungal ef-
ficacy  of  each  drug  was  expressed  by  measure-
ment of the diameter of the inhibition zone, using 
“pbi  Readbiotic”  (pbi  international,  Milano,  Italy) 
measuring device, present around the well which 
accommodated the DRD that contained the specific 
drug. 
Each experiment was carried out five times for 
each antifungal drug doped-DRD and was corre-
lated against the controls.
Figure 4. A representative chromatogram of a standard mix-
ture of Chlorhexidine with the internal standard.
Figure 6. Line diagram plotting the cumulative drug conc (µg/
ml) versus time (days) for FNZ, CHX, and FNZ+CHX combina-
tion, demonstrating the sustained release of the drugs over the 
four weeks test period.
Figure 5. A representative chromatogram of a standard mix-
ture combining Fluconazole and Chlorhexidine.
Figure 7. Saborauds culture medium inoculated with Candida 
albicans. Note the three wells prepared to accommodate the 
eluates from Fluconazole (10%), Chlorhexidine (10%), and the 
combination drug (5% Fluconazole + 5% Chlorhexidine) discs 
soaked in distilled water at mouth temperature.
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Statistical analysis
Statistical  Package  for  Social  Sciences  soft-
ware (SPSS, version 16.0, Inc., Chicago, IL, USA) 
was employed in the analysis of the various data 
sets. The differences in the release behavior of 
Fluconazole, chlorhexidine, and the combination 
release were determined by Kruskal-Wallis test. 
The differences in diameter values of the Inhibi-
tion Zones of Candida albicans growth produced 
by Fluconazole, Chlorhexidine, and the combina-
tion  of  the  two  drugs  after  24  hours  incubation 
were determined using the paired-sample t-test. 
All statistical tests were performed at 0.05 level 
of confidence.
rEsuLts
Drug release device (DRD)
At the outset, the incorporation with the room 
temperature polymerized poly (methyl methacry-
late) acrylic resin (PMMA) of any of the two em-
ployed antifungal drugs did not have any untoward 
effect on the polymerization reaction of the PMMA 
or on the preparation of the test sample.
HPLC analysis of the drug release
The  antifungal  drugs  contained  in  the  disc 
specimens, namely, Fluconazole (10%), Chlorhex-
idine (10%), and the combination of the two drugs 
(5%  Fluconazole  and  5%  Chlorhexidine)  dem-
onstrated an initial high rate of elution from the 
PMMA reservoir (DRD) during the first 2-7 days 
followed by a controlled-elution process of sus-
tained release that continued throughout the 28 
days test period (Table 1, Figure 6). In general, al-
though the two individual drugs as well as their 
combination revealed a comparable elution pro-
file but in comparison, Chlorhexidine displayed a 
substantially higher release rate than Fluconazole 
(P<.05), attaining a concentration of up to 606 µg/
ml which is equivalent to 36.4 mg of the drug re-
leased after one day compared to 128 µg/ml of 
Fluconazole which is equivalent to 7.7 mg of the 
drug released during the same period.  The rate of 
release from the samples that combined the two 
antifungal drugs was significantly higher than that 
of the individual drugs (P=0.002). It combined the 
release rates of the two drugs, and attained a re-
markably high released concentration (734 µg/ml) 
which was equivalent to 44.1 mg of the combined 
drugs after only one day of exposure distilled wa-
ter.
Microbiology
The  percolate  from  the  DRD  that  contained 
10% Fluconazole and that which contained 10% 
Chlorhexidine and the DRD that contained a com
Figure 8. Demonstrating the zone of inhibition of the Candida 
albicans growth around the well that contained the DRD with 
10% Fluconazole antifungal drug. Note the absence of an inhi-
bition zone around the well that contained the control, i.e., the 
DRD alone.
Figure 10. Demonstrating a remarkably wide zone of inhibition 
of the Candida albicans growth around the well that contained 
the  DRD  with  combined  antifungal  drugs,  5%  Fluconazole 
and 5% Chlorhexidine. Note the absence of an inhibition zone 
around the well that contained the control, i.e., the DRD alone. 
Figure 9. Demonstrating the zone of inhibition of the Candida 
albicans growth around the well that contained the DRD with 
10% Chlorhexidine antifungal drug. Note the absence of an in-
hibition zone around the well that contained the control, i.e., 
the DRD alone.
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bination of 5% of each antifungal drug showed a 
clear antifungal activity. This was demonstrated 
by the occurrence of zones of inhibition of Candida 
albicans growth around the wells that contained 
the DRDs with the drugs compared with the con-
trols, i.e., DRD alone (Figures 8-10). However, the 
three types of DRDs varied in their antifungal po-
tential, with DRD containing Chlorhexidine show-
ing a significantly higher antifungal potential than 
that containing Fluconazole (P<.05). The most ef-
fective antifungal activity was demonstrated by the 
DRD that contained the combined drugs (P=0.002) 
(Table 2, Figure 11).
The  antifungal  drugs,  Chlorhexidine,  Flucon-
azole and the combination of the two drugs, con-
tained in the DRDs continued to display the same 
ranking of antifungal potential throughout the 28 
days test period. This was demonstrated by the 
plot of the width of the inhibition zone of Candida 
albicans growth versus time (Figure 12). 
dIscussIon
The release of Fluconazole and/or Chlorhexi-
dine  from  the  poly  (methyl  methacrylate),  drug 
release devices, to distilled water indicated that 
polymerization of the PMMA acrylic resin did not 
adversely affect the two antifungal drugs nor did 
doping the PMMA acrylic resin with Fluconazole or 
Chlorhexidine alter the diffusion characteristics of 
the resin. This finding is in agreement with previ-
ously reported studies that employed polymers for 
delivering Chlorhexidine.9,10 
Elution  of  Fluconazole  antifungal  drug  from 
auto-polymerized acrylic resin specimens doped 
Figure 11. Comparing the zones of inhibition of the Candida 
albicans growth around the wells that contained the antifungal 
drugs. Note the remarkably wide inhibition and dilution zones 
around  the  well  accommodating  the  combined  Fluconazole 
and Chlorhexidine indicating a synergistic effect of the two an-
tifungal drugs.
Figure 12. A histogram plotting the width of the inhibition zones 
of the Candidal growth affected by Fluconazole, Chlorhexidine, 
and the combination of the two antifungal drugs over the four 
weeks test period. 
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(µg/ml) (mg) (µg/ml) (mg) (µg/ml) (mg)
1 128A 7.68a 606B 36.4b 734C 44.1c
7 202A 12.12a 803B 48.2b 1005C 60.3c
14 229A 13.74a 885B 53.1b 1114C 66.8c
21 242A 14.52a 946B 56.8b 1188C 71.3c
28 249A 15.00a 974B 58.4b 1223C 73.4c
Table 1. Mean concentration (µg/ml) and amount (mg) values (Ƞ=5) of the antifungal drugs released from the auto-
polymerized acrylic discs into distilled water at weekly intervals for the 28 days test period. (Different upper case 
or lower case alphabets in rows denote significant difference at P=0.002)European Journal of Dentistry
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by Fluconazole demonstrated a relatively high ini-
tial release of the drug into distilled water during 
the first four days. A similar diffusion profile was 
demonstrated by Chlorhexidine. However, the dif-
fusion gradient of Chlorhexidine was significantly 
higher than that of Fluconazole. 
For both drugs, following the initial elution at a 
high rate, the release of the antifungal drugs dem-
onstrated a slower and steadier diffusion for up to 
twenty eight days. The change in the rate of drug 
release is attributed to the fact that the leaching 
behavior  of  Fluconazole  and  Chlorhexidine  into 
distilled water is governed by a concentration de-
pendent diffusion process.10 Although the two an-
tifungal  drugs  demonstrated  somewhat  similar 
general elution behavior, the rate of release, how-
ever, was substantially higher for Chlorhexidine 
than that of Fluconazole. This was indicated by the 
release of higher concentrations of Chlorhexidine 
into  distilled  water  throughout  the  twenty  eight 
days test period compared to Fluconazole which 
showed release of significantly lower concentra-
tions to distilled water. 
Similar elution profile was reported for residu-
al un-polymerized methyl methacrylate monomer 
from  the  same  auto-polymerizing  acrylic  resin 
when exposed to both distilled water and artificial 
saliva at mouth temperature.11,12 
The results of the present investigation high-
lighted  the  remarkable  release  behavior  of  the 
combined  antifungal  drugs  (Fluconazole  and 
Chlorhexidine 5% w/w each) contained within the 
PMMA DRD. The diffusion profile revealed by the 
drug combination DRD demonstrated significantly 
higher concentrations of the released drugs than 
the released concentration of either drug individu-
ally. The enhanced drug release behavior demon-
strated by the drug combination DRDs was con-
sistently high at the outset and continued to be 
significantly improved throughout the four weeks 
test period. 
It has been clearly established that methacry-
late-based polymers absorb up to 30% water de-
pending on the osmolarity of the external solution9 or 
the formulation of the particular polymer.9-11 The 
mechanism of elution seemed to consist of two 
phases, a rapid linear behavior obeying Fick’s law, 
followed by the development of discrete clusters 
of the immersion liquid of an un-identified osmotic 
activity.10
In  the  presence  of  the  antifungal  drugs, 
Chlorhexidine and/or Fluconazole, the rapid elu-
tion  phase  probably  indicates  surface  release 
process. The subsequent slow phase of sustained 
release may be the result of complex processes 
involving  formation  of  fluid  clusters  around  the 
drug molecules and the interaction of these clus-
ters with the mechanism of fluid absorption of the 
acrylic resin. Similar behavior has been reported 
for the release into distilled water but of a differ-
ent  drug  from  a  methacrylate-based  polymeric 
system.9
The elution behavior of Chlorhexidine and/or 
Fluconazole may also be enhanced by crazes and 
surface porosity, formed in the brittle poly (methyl 
methacrylate) by the osmotic forces consequent 
on the inclusion of the antifungal drug. This is con-
sistent with previously reported finding of a study 
that used the same polymeric system for delivery 
of hydrocortisone.13
 Having established that a Chlorhexidine and/
or Fluconazole-supplemented polymeric devices 
do release the antifungal drugs in controlled con-
centrations for up to four weeks, it became essen-
tial to investigate whether the concentrations of 
the released drugs were high enough to affect an 
antifungal activity upon the growth of Candida al-
bicans which is the common pathogen that causes 
denture-induced stomatitis lesions. This entailed 
the microbiological investigation conducted in this 
study which ascertained that the released concen-
trations of the antifungal drugs did induce antifun-
gal effect against Candida albicans by inhibiting 
its growth in Saborauds culture for the entire four 
weeks test period. 
Antifungal Drug Zone of inhibition in (mm)
Fluconazole 10% 20
Chlorhexidine 10% 25
Fluconazole 5%+ Chlorhexidine 5% 55
Table 2. Diameter of the inhibition zones of Candida albicans growth produced by Fluconazole, Chlorhexidine, and 
the combination of Fluconazole and Chlorhexidine after incubation. Each value is the mean diameter of five dupli-
cate trials  and was corrected with the control cups. A score of  10 mm or less was considered insignificant. 
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These findings confirmed those of an earlier 
study14 which also showed that Chlorhexidine dif-
fuses out of an auto-polymerized acrylic resin in 
fungicidal concentrations over a period of at least 
three weeks.
The results of the present investigation indicat-
ed that Chlorhexidine-supplemented DRD had a 
more powerful antifungal effect, proved by its ca-
pacity of inhibiting the growth of Candida albicans, 
than that of Fluconazole contained DRD. The re-
sults also indicated that the DRD which was sup-
plemented by a combination of the two drugs in a 
5% concentration of each had the most powerful 
antifungal potential against the growth of Candida 
albicans, thus indicating a possible synergistic ef-
fect of the two drugs. 
This is an interesting finding since it encour-
ages the use of combinations of antifungal drugs 
in low concentrations, thus reducing the chance of 
developing an allergic reaction to the drugs by the 
host, yet possessing a substantially high antifun-
gal potential.  
In the clinical context, the cumulative nature 
of Chlorhexidine and Fluconazole release into the 
surrounding fluid media helps saturate the sali-
vary film which bathe the tissue surface of a den-
ture base with a continuous release bouts of the 
antifungal drugs.
concLusIons
Within the limitations of the present investiga-
tion incurred by employing only one resin system 
for the intraoral delivery of antifungal drugs; and 
by evaluating the efficacy of the drugs upon the 
growth of only one candidal species, candida albi-
cans, rather than a wider range of pathogens. The 
following conclusions, however, may be attained:
• Fluconazole, chlorhexidine and a combina-
tion of the two antifungal drugs can be success-
fully  incorporated  with  auto-polymerized  poly 
(methyl methacrylate)
• These drugs leach out of the polymer into 
the surrounding fluid medium in an environment 
similar to that of the oral cavity with respect to hu-
midity and temperature.
• A sustained incremental elution of the anti-
fungal drugs from the doped-polymeric denture 
base  maintains  a  gradually  increasing  concen-
tration of the drugs at the exact site of pathology 
where Candidal infection lesions of the tissue bed 
of the maxillary denture are usually found. 
• The results of the microbiological investiga-
tion confirmed the antifungal efficacy of the drug-
supplemented delivery systems and favored the 
use of polymeric systems doped with a combina-
tion of antifungal drugs in small concentrations. 
Future investigations should be carried out to 
evaluate the antifungal efficacy of the suggested 
system against a wider range of pathogens from a 
higher number of clinical isolates. Similar in vitro 
studies employing different polymeric systems for 
a sustained intraoral release of antifungal drugs 
should be encouraged. Clinical studies are essen-
tial in order to test the efficacy of the suggested 
drug-delivery  system,  before  implementing  the 
new dosage form of antifungal drugs for the treat-
ment of denture-associated oral Candidiasis.
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